Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drug products after the expiration of the national organized procurement agreements, with 13 products, including Bisoprolol Fumarate Tablets and Etoricoxib Tablets, proposed for selection in this procurement [1] Group 1 - The procurement process is led by Jiangsu, Henan, and Guangdong provinces, aiming to stabilize or further reduce prices while providing greater choice for medical institutions [1] - The selection of products allows medical institutions to choose suppliers with better supply assurance capabilities, thereby ensuring continuity in clinical medication and reducing the risks associated with drug switching due to centralized procurement [1] - Although some selected products have lower prices compared to previous sales, the selection of 13 products positions the company to maintain its market share and enhance the accessibility of these drugs if contracts are signed and executed [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has participated in the procurement process for the continuation of drug selection following the expiration of the national organized procurement agreements, with 13 products, including Fumarate Bisoprolol Tablets and Etoricoxib Tablets, proposed for selection in this round of procurement [1] Group 1 - The procurement process is organized by Jiangsu, Henan, and Guangdong provinces, aiming to stabilize or further reduce drug prices while providing greater choice for medical institutions [1] - The selection of 13 products by the company, despite some price reductions compared to original sales prices, is expected to help maintain market share and enhance drug accessibility if contracts are signed and executed [1] - The procurement aims to ensure continuity in clinical medication and reduce the risks associated with drug switching due to organized procurement [1]

Core Viewpoint - The company, through its subsidiaries, is participating in a national centralized procurement process for pharmaceuticals, which could enhance its market share and brand influence if selected products are confirmed and contracts are signed [1] Group 1: Company Participation - The company’s wholly-owned subsidiaries and a controlling subsidiary are involved in the national centralized procurement for expiring drug agreements [1] - The procurement office announced the proposed selection results for the procurement on February 10, 2026 [1] Group 2: Potential Impact - If the proposed selected products are confirmed and contracts are signed, it will help the company expand sales of related products [1] - The successful procurement will ensure that medical institutions prioritize the selected drugs, which is expected to positively impact the company's future operating performance [1]

Group 1 - The company, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., have participated in the national centralized procurement for the continuation of products from the first to eighth batches, with results published on February 10, 2026 [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which will last until December 31, 2028 [1] - The procurement volume will be based on the demand reported by medical institutions, with pricing determined by a tiered selection process [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798.19 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is around RMB 550.45 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it is expected to further increase product sales, enhance market share, and improve the company's brand image, positively impacting future business development [2]

Core Viewpoint - The company, Asia-Pacific Pharmaceutical (002370.SZ), has participated in the continuation procurement organized by the National Organization for Drug Procurement, with 13 products, including injectable Cefmetazole Sodium and Febuxostat tablets, proposed for selection in the continuation procurement process [1] Group 1: Procurement Details - The continuation procurement involves products from the first to eighth batches of the national organized procurement agreements that have expired [1] - The agreed procurement volume for each product will be based on the demand reported by medical institutions, with the selection price gradient determining the volume ratio [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this continuation procurement during the procurement period, ensuring the completion of the agreed procurement volume [1] - If the company signs procurement contracts and implements them, it will further expand the sales of related products, enhance market share, and improve brand influence, positively impacting future operating performance [1]

Core Viewpoint - The company Fu Yuan Pharmaceutical (601089.SH) announced participation in the national organized procurement for drugs whose agreements are expiring, with selected products including Ezetimibe tablets, which are expected to positively impact future operating performance despite a decrease in sales prices [1] Group 1: Procurement Participation - The company participated in the national organized procurement for drugs with expiring agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions signing procurement contracts based on the selected results [1] Group 2: Market Impact - Selected products in this procurement, including Ezetimibe tablets, are anticipated to have a decrease in sales prices [1] - The company aims to stabilize its existing market share and potentially increase market penetration due to brand influence and reliable supply capabilities [1] - The positive impact on the company's future operating performance is expected as a result of these developments [1]

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), participated in the national organized procurement for drugs whose agreements are expiring, with selected products expected to positively impact future business performance despite a decrease in sales prices [1] Group 1: Procurement Participation - The company announced its participation in the national organized procurement for drugs with expiring agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions signing contracts based on the selected results [1] Group 2: Selected Products and Market Impact - The company has several products, including Ezetimibe tablets, proposed for selection in this procurement [1] - Although the sales prices of selected drugs are expected to decrease, the company aims to stabilize its existing market share and potentially increase market penetration due to its brand influence and reliable supply capabilities [1]

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), has participated in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in the upcoming procurement results, which will positively impact its market share and future performance [1]. Group 1: Procurement Participation - On February 9, 2026, the company participated in the national organized procurement for drugs with expired agreements [1]. - The procurement results are expected to be implemented by the end of March 2026, allowing provincial medical institutions to sign contracts with manufacturers based on the selected results [1]. Group 2: Market Impact - Although the sales prices of the selected drugs are expected to decrease, the company aims to stabilize its existing market share [1]. - The company is positioned to potentially increase its market share due to its brand influence and reliable supply capabilities, which will have a positive effect on its future operating performance [1].

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), participated in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in the upcoming procurement results [1] Group 1: Procurement Details - The company attended the national organized procurement for drugs with expired agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions beginning to sign procurement contracts based on the selected results [1] Group 2: Market Impact - Although the sales prices of the selected drugs are expected to decrease, the company aims to stabilize its existing market share [1] - The company is positioned to potentially increase its market share due to its brand influence and reliable supply capabilities, which may positively impact its future operating performance [1]

Core Viewpoint - The company, China Resources Double Crane (华润双鹤), is participating in a national procurement process for pharmaceutical products, with some of its drugs expected to be selected in the upcoming procurement results, which will be implemented by the end of March 2026 [1][2] Group 1: Company Performance - In the first three quarters of 2025, the sales revenue of Valsartan and Hydrochlorothiazide tablets was 426 million yuan, accounting for 5.14% of the total revenue [1] - The sales revenue of Nifedipine Controlled-Release Tablets was 138 million yuan, representing 1.67% of the total revenue [1] - The sales revenue of Enoxaparin Sodium Injection was 119 million yuan, making up 1.43% of the total revenue [1] - The sales revenue of Nifedipine Sustained-Release Tablets (II) was 108 million yuan, accounting for 1.30% of the total revenue [1] - The sales revenue of Irbesartan Dispersible Tablets was 79 million yuan, which is 0.95% of the total revenue [1] Group 2: Industry Context - The upcoming procurement process aims to maintain stable or decreasing prices, providing medical institutions with greater choice among selected suppliers, which helps ensure continuity in clinical medication and reduces the risk of medication switching due to centralized procurement [2] - Although the selection may lead to a decrease in overall sales revenue, it is expected to solidify the company's existing market share, with potential for increased market penetration due to brand influence and reliable supply capabilities [2]